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Toxoplasma gondii commonly infects humans and while most infections are controlled by the
immune response, currently approved drugs are not capable of clearing chronic infection in
humans. Hence, approximately one third of the world’s human population is at risk of
reactivation, potentially leading to severe sequelae. To identify new candidates for treating
chronic infection, we investigated a series of compounds derived from diversity-oriented
synthesis. Bicyclic azetidines are potent low nanomolar inhibitors of phenylalanine tRNA
synthetase (PheRS) in T. gondii, with excellent selectivity. Biochemical and genetic studies
validate PheRS as the primary target of bicyclic azetidines in T. gondii, providing a structural
basis for rational design of improved analogs. Favorable pharmacokinetic properties of a lead
compound provide excellent protection from acute infection and partial protection from
chronic infection in an immunocompromised mouse model of toxoplasmosis. Collectively,
PheRS inhibitors of the bicyclic azetidine series offer promise for treatment of chronic
toxoplasmosis.
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oxoplasma gondii is a widespread parasite of animals that
causes zoonotic infections in people, infecting up to a
third of the world’s human population1. Acute infections
caused by the actively proliferating tachyzoite stage are generally
well controlled by the immune system2,3. In response, the parasite
differentiates to a chronic stage called the bradyzoite that resides
within tissue cysts that form primarily in muscle and brain4,5.
The residence of these semi-dormant stages in sites of immune
privilege like the brain, combined with their propensity to reactivate in response to declining systemic immunity, poses great
risk due to re-emergence of actively proliferating tachyzoites
that destroy tissue6. Additionally, healthy adults are at risk of
recurrent ocular toxoplasmosis that can result in loss of vision
due to infections that are more severe and difﬁcult to treat in
some regions, such as South America7. The current treatment for
toxoplasmosis is based on inhibition of the folate pathway that is
required for nucleotide synthesis in the parasite8. Such a strategy
targets actively-replicating tachyzoites but spares bradyzoites,
which reside within cysts in the host’s muscle and brain tissue8
and divide infrequently and asynchronously9. In order to successfully target the chronic tissue stages, compounds would thus
need to be effective in crossing the blood-brain barrier, accumulating in the CNS, and target an essential process in the semidormant bradyzoite stage of the life cycle. This challenge is
complicated by the relative lack of knowledge of what pathways
are essential in bradyzoites10.
A recent high-throughput screen (HTS) for small molecules that
would act synergistically with interferon-gamma (IFN-γ)11 identiﬁed several potent hits from the diversity-oriented synthesis (DOS)
small-molecule library developed at the Broad Institute12,13. The
DOS library, enriched in compounds typically underrepresented
in commercial screening libraries, has proven valuable in identifying
novel-mechanism-of-action probes and drug leads14. Bicyclic
azetidines derived from DOS libraries have recently been
shown effective in single-dose efﬁcacy against multiple stages of
Plasmodium spp., including both rapidly replicating asexual blood
stages and slow-replicating or dormant hypnozoite stages15. Bicyclic
azetidines have also been shown to be highly potent inhibitors
of Cryptosporidium spp.16,17. In both cases, efﬁcacy has been
demonstrated in vitro and using mouse models of parasitic
infection. Bicyclic azetidines have been shown to target apicomplexan phenylalanine tRNA synthase (PheRS)15,16,18. This essential
enzyme that differs sufﬁciently from its human counterpart, making
it an excellent target for the development of new therapeutics.
In the present study, we analyzed a series of bicyclic azetidines
for their ability to inhibit T. gondii growth in vitro as tachyzoites,
to target bradyzoites from tissue cysts produced in vivo, and to
protect against acute and chronic toxoplasmosis in a relevant
mouse model. Several compounds in this series exhibited high
potency and selectivity for inhibition of T. gondii PheRS and
provided effective inhibition of parasite growth in vitro and
in vivo. These ﬁndings suggest that PheRS inhibitors based on the
bicyclic azetidine scaffold deserve further attention as multistage
inhibitors of T. gondii.
Results
Bicyclic azetidines are potent inhibitors of T. gondii tachyzoite
growth. In light of prior studies demonstrating the efﬁcacy of
PheRS inhibitors against apicomplexan parasites15,16,18, we
assessed the activity of 28 structurally unique compounds from
the bicyclic azetidine series to determine their activities against
the type II ME49 strain expressing ﬁreﬂy luciferase (FLuc)19
tachyzoites of T. gondii using a luciferase-based growth screen to
determine half-maximal effective concentration (EC50) (Fig. 1a,
Table S1). All compounds had EC50 values lower than 5 μM,
2

Fig. 1 Bicyclic azetidines are potent inhibitors of T. gondii tachyzoite
growth. a Rank order based on median effective concentration (EC50)
determination of compounds from the bicyclic azetidine series against
growth of T. gondii tachyzoites in vitro. Values represent average of two
biological replicates used to calculate the EC50 value with 10-point
dose–response curves. The four most potent compounds are highlighted:
BRD2987 (0.0195 μM, green); BR7929 (0.0226 μM, red); BRD3444
(0.0289 μM, blue) and BRD8494 (0.0348 μM, purple). Pyrimethamine
(0.248 μM, open circle) highlighted for reference. A stepwise description of
chemical synthesis scheme for BRD2987 is found in Fig. S1. A complete list
of EC50 values for all 28 bicyclic azetidines screened is found in Table S1.
b Chemical structures of most potent bicyclic azetidines: BRD2987,
BRD7929, BRD3444, and BRD8494, which differ only in the nature of
appendages (R1, R2) as indicated. Source data are provided as a Source
Data ﬁle.

including thirteen compounds with greater potency than pyrimethamine (EC50 = 0.248 μM), which is part of the current
standard of care (Fig. 1a). Among this series, ten compounds had
sub 0.1 μM EC50 values for T. gondii growth inhibition (Table S1).
Four lead compounds were selected for further evaluation based
on potency against the tachyzoite stage (Fig. 1a): BRD2987
(green, EC50 = 0.0185 μM), BRD7929 (red, EC50 = 0.023 μM),
BRD3444 (blue, EC50 = 0.0289 μM) and BRD8494 (purple,
EC50 = 0.0348 μM), differing in chemical substituents on the aryl
urea (R1) and azetidine ring (R2, Fig. 1b). To test whether bicyclic
azetidines were potent against multiple genetic lineages of T.
gondii, we engineered FLuc expression into eight independent
genetic backgrounds20 (Table S2). BRD7929 was highly potent
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Table 1 Determination of EC50 values of BRD7929
against ﬁreﬂy luciferase expressing parasites from a diverse
cross section of T. gondii genotypes.
Strain

Type

Origin

EC50 (nM)

SD

GT1
RH
ME49
CTG
MAS
RUB
FOU
VAND

I
I
II
III
IV
V
VI
X

N. America
Europe
Europe
N. America
Europe
S. America
Europe
S. America

16.07
24.14
49.42
31.53
41.97
26.89
45.13
27.94

7.78
3.93
9.29
8.20
15.61
9.55
12.22
6.66

against all lineages with EC50 values less than 50 nM against
tachyzoite growth in vitro (Table 1).
Bicyclic azetidines display similar activity against apicomplexan parasites. To further understand the mechanism of action
of bicyclic azetidines against T. gondii, we examined the correlation between EC50 values for T. gondii tachyzoites with EC50
values of blood-stage P. falciparum for which corresponding data
was available15. We found a strong positive correlation for twenty
compounds including the most potent inhibitors of T. gondii
tachyzoites and blood-stage P. falciparum growth (Fig. 2a). Furthermore, we analyzed the stereochemical speciﬁcity of BRD3444
by comparing the EC50 values from T. gondii and P. falciparum of
this compound to those of its seven stereoisomers (Fig. 2b). The
choice of BRD3444 in these assays was driven largely by the fact
that we had all eight stereoisomers available for testing in parallel
and there were existing data for P. falciparum. The highest
activity against both parasites is associated with the S, R, R (C2,
C3, C4) and R, R, R isomers (Fig. 2b), indicating that the shared
stereochemical conﬁguration is critical to potency. The strong,
positive correlation within the bicyclic azetidine scaffold and the
nearly identical stereochemical selectivity for BRD3444 against T.
gondii and P. falciparum imply a shared molecular target and
mechanism of action. Expanding on this observation, we next
correlated the EC50 values of six bicyclic azetidines previously
screened against C. parvum16 with T. gondii values (Fig. 2a).
Indeed, a strong correlation of activity was identiﬁed (Fig. 2a)
between these parasites, including BRD3444 which was one of the
most potent inhibitors of T. gondii growth (Fig. 1a) and which
reduced oocyst shedding by 96% in a C. parvum mouse model of
infection16. To broaden the potential therapeutic use of the series
against other apicomplexans and infer common mechanisms of
action, we determined the EC50 values of eight bicyclic azetidines
against the veterinary pathogen Neospora caninum (Fig. S2) with
a 10-dose–response curve based on a transgenic N. caninum
parasite expressing lacZ21 (Table S3). Although only a small set of
compounds were tested against N. caninum, they showed similar
potencies to their activities against T. gondii as shown by linear
regression (r2 = 0.69) (Fig. S2). Similar to T. gondii, BRD2987
and BRD7929 were among the most potent compounds against
N. caninum (Fig. S2, Table S3). Taken together, the strong
positive correlation of potency of the bicyclic azetidine series
against multiple species further supports a shared mechanism of
action for bicyclic azetidines against apicomplexan parasites.
Bicyclic azetidines inhibit T. gondii phenylalanine tRNA synthetase (TgPheRS). Previous studies of Plasmodium and Cryptosporidium parasites identiﬁed cytoplasmic tRNA synthetase
(PheRS) as the parasite target of the bicyclic azetidine chemical
series15,16. The PheRS enzyme is highly conserved among

Fig. 2 Bicyclic azetidines inhibit the growth of multiple species of
Apicomplexa. a Correlation of growth inhibition for T. gondii (Tg)
tachyzoites compared with blood-stage P. falciparum (Pf)15 (black
regression line, r2 = 0.89, P < 0.0001) based on EC50 values for different
bicyclic azetidines. A similar correlative analysis between T. gondii and C.
parvum (Cp) (Tg vs Cp, open squares) EC50 values for bicyclic azetidines
(dashed regression line, r2 = 0.84, P = 0.0102). Colored circles (Tg vs Pf)
or squares (Tg vs Cp) highlight four lead compounds as identiﬁed in Fig. 1:
BRD2987 (green); BR7929 (red); BRD3444 (blue) and BRD8494 (purple).
See Table S2 for all EC50 values against C. parvum16. b Stereospeciﬁcity of
antiparasitic activity of bicyclic azetidine BRD3444. Chemical structures
and in vitro antiparasitic activity of bicyclic azetidine BRD3444 and its
seven stereoisomers; repeated appendages are depicted as gray beads for
clarity, and the stereochemical conﬁguration of C2, C3, C4 is indicated
(yellow boxes). Half-maximal effective concentrations of in vitro inhibition
of T. gondii growth are shown (EC50, green boxes, calculated as the mean of
two biological replicates ± SEM.); previously reported EC50 values of in vitro
inhibition of P. falciparum growth15 are indicated for comparison (gray
boxes). Source data are provided as a Source Data ﬁle.

apicomplexans and mutations that confer resistance to bicyclic
azetidines are conserved between P. falciparum15 and C. parvum16.
In order to identify the target of bicyclic azetidines in T. gondii, we
selected for resistance in vitro using the compound BRD7929 due
to favorable PK properties15 that made it suitable also for in vivo
infection studies described below. We evolved resistance to
BRD7929 in two parallel, independent pools of parasites that were
selected by sequential passages over the course of ~5 months
(Fig. 3a). We determined the EC50 value of each pool using a
luciferase-based growth assay to monitor BRD7929 sensitivity
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Fig. 3 Resistance to BRD7929 correlates to resistance-conferring mutations identiﬁed in P. falciparum. a Evolved resistance to BRD7929 in T. gondii
(RH-FLuc strain) by serial passage at sub-lethal concentrations. Two independent pools of BRD7929 resistant parasites were selected over 152 days of
continuous culture in increasing concentrations of BRD7929. Pool 1 = 1.0 μM ﬁnal concentration, 12 passages, red line and circles; Pool 2 = 5.0 μM ﬁnal
concentration, 18 passages, blue line and boxes. Stepwise increase in BRD7929 started at 0.1 μM for both pools. Genomic DNA for whole-genome
sequencing (WGS) was collected for analysis from each pool at day 152. b EC50 determination of BRD7929 resistant pools using a 10-point dose–response
curve. Parent (RH-FLuc) = black circles and line; pool 1 = red squares and line; pool 2 = blue squares and line. c Evaluation of EC50 for T. gondii tachyzoites
engineered to carry TgPheRS resistance-conferring mutations TgPheRS[L497V] and TgPheRS [L497I]. d Evaluation of EC50 for T. gondii tachyzoites
engineered to carry TgPheRS resistance-conferring mutations TgPheRS[M484I] TgPheRS[V262Aand the double mutant. Mutant lines are shown color; the
wild-type RHΔΔ parent is shown in black. All EC50 values are presented as the mean of three biological replicates ± SEM (n = 3). Source data are provided
as a Source Data ﬁle.

relative to the parental line (Fig. 3b). Pool 1 (EC50 = 0.130 μM, red
line) and pool 2 (EC50 = 1.40 μM, blue line) showed resistance to
BRD7929 ranging from 10- to 100- fold, respectively (Fig. 3b).
Subsequent whole-genome sequencing identiﬁed three nonsynonymous single nucleotide variants (SNV) associated with
BRD7929 resistance in the gene encoding the alpha subunit of
cytosolic PheRS (i.e. TGGT1_2345050, ToxoDB.org). The SNVs
encoded new amino acid changes at positions TgPheRS[L497I] (pool
1) TgPheRS[V262A] (pool 2), and TgPheRS[M484I] (pools 1 and 2) in
TgPheRS (Fig. 3a). The mutation TgPheRS[L497I] occurred in the
residue corresponding to the previously described resistance
mutation PfPheRS[L550V] in P. falciparum15, while the other
mutations were unique to T. gondii (Fig. S3). To determine if these
amino acid changes conferred resistance to BRD7929, we used a
CRISPR/Cas9-based markerless editing strategy to introduce point
mutations into a wild-type T. gondii background (type I, RH strain
lacking hxgprt and ku8022) and evaluated growth using a modiﬁed
parasite lytic assay23. Mutation of TgPheRS[497] from a leucine to
either a valine to mimic the P. falciparum mutation, or isoleucine
4

as seen in T. gondii (Fig. 3c), resulted in 40–60-fold changes in
EC50 values over the parent strain, indicating that these single point
mutations indeed confer resistance to BRD7929. Single point
mutations of methionine to isoleucine (TgPheRS[M484I]) or valine
to alanine at position 262 (TgPheRS[V262A]), only shifted the EC50
value 2 or 4-fold, respectively (Fig. 3d). Sequential introduction of
the TgPheRS[M484I] and TgPheRS[V262A] mutations to generate a
double mutant only shifted the EC50 slightly more than every single
mutation (Fig. 3d), consistent with the lower overall resistance of
pool 1. We did not detect any difference in the ﬁtness of the
mutant lines based on plaque formation or lytic growth on ﬁbroblast (HFF) monolayers (Fig. S4). Collectively, the identiﬁcation
and re-introduction of mutations in TgPheRS that confer tachyzoite growth in the presence of BRD7929 strongly suggest that
PheRS is the primary target of the bicyclic azetidines in T. gondii.
BRD7929 is a potent and selective inhibitor of TgPheRS.
To provide further support that TgPheRS is the molecular target
of bicyclic azetidines, we assayed the compound against puriﬁed
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Fig. 4 BRD7929 is both selective for and potent against TgPheRS. a Determination of the median inhibition concentration (IC50) of BRD7929 for T. gondii
TgPheRS (green) versus human HsPheRS (red) using a 10-dose–response curve. b Inhibition curves for wild-type TgPheRS enzyme (black) vs. TgPheRS
containing resistance-conferring point mutations. Average of three biological replicates each with two technical replicates (n = 6) ± SEM. c Homology
models showing catalytic pocket of PfPheRS (gray) and TgPheRS (blue) in the α-subunit superimposed on the structure of TtPheRS-L-Phe-AMP-tRNA
(yellow, PDB 2IY5). The drug-resistant PfPheRS and TgPheRS mutations are highlighted in green and red, respectively. Source data are provided as a
Source Data ﬁle.

Table 2 Evaluation of host cell toxicity for bicyclic azetidines.
T. gondii HEPG2

HFF

THP-1

SH-SY5Y

A549

Caco-2

ID

EC50
(μM)

EC50
(μM)

fold
EC50
selectivity (μM)

fold
EC50
selectivity (μM)

fold
EC50
selectivity (μM)

fold
EC50
selectivity (μM)

fold
EC50
selectivity (μM)

fold
selectivity

BRD7929
BRD3444
BRD8494
BRD2987

0.023
0.029
0.035
0.019

3.065
11.327
20a
20a

133.3
390.6
571.4
1052.6

342.3
689.7
571.4
1052.6

29.2
88.9
13.2
13.4

31.8
91.9
51.0
123.9

233.7
693.2
571.4
114.0

304.5
269.52
571.4
1052.6

7.872
20a
20a
20a

0.672
2.578
0.461
0.255

0.731
2.665
1.785
2.355

5.374
20a
20a
2.166

7.003
7.816
20a
20a

EC50 values based on two biological replicates each with two technical replicates. Values represent means.
aCurve ﬁtting EC values for these compounds were greater than the highest drug concentration (20 μM) used in the screen. 20 μM was used to determine fold selectivity. Fold selectivity was
50
calculated as EC50 host cell/EC50 T. gondii.

recombinant proteins for human (HsPheRS) and wild-type
TgPheRS (Fig. 4a). In these studies, we focused on BRD7929
due to its superior PK properties15 that made it a better candidate
for in vivo studies described below. First, we determined the halfmaximal inhibitory concentration (IC50) for BRD7929 against
HsPheRS and TgPheRS to evaluate selectivity for the parasite
enzyme over the host enzyme (Fig. 4a). BRD7929 inhibited
TgPheRS in a concentration-dependent manner and was >600fold selective for the parasite enzyme (Fig. 4a) Consistent with
this ﬁnding, the most active bicyclic azetidines showed minimal
toxicity for host cells and greater than 100-fold selectivity for
inhibiting parasite growth over host cell lineages such as ﬁbroblasts (HFF), lung endothelial cells (A549), kidney hepatoma cells
(HepG2) and intestinal epithelium (Caco-2) (Table 2). Somewhat
greater toxicity was seen using a human monocyte like tumor line
(THP-1) or a neuroblastoma cell line (SH-SY5Y), although even
with these more sensitive lines there was greater than 10-fold, and
in most cases > 30-fold, selectivity for parasite growth inhibition
vs. host (Table 2). Introduction of resistance-conferring

mutations at amino acid TgPheRS[L497V], which mimics the
change seen in P. falciparum, shifted the IC50 ~60-fold (Fig. 4b).
Additionally, the introduction of the new point mutations seen
in resistant populations of T. gondii into the wild-type enzyme
shifted the IC50 values (Fig. 4b), with the most dramatic changes
resulted from the mutation of TgPheRS[L497I]. Much smaller
differences were observed in the single mutants TgPheRS[M484I],
TgPheRS[V262A] or the corresponding double mutant (Fig. 4b).
Overall, there was an excellent correlation between the IC50
values of enzyme inhibition and EC50 values for parasite growth
inhibition (r2 = 0.92 (Table S4)). To illustrate amino acid
changes associated with BRD7929 resistance, we modeled
TgPheRS and PfPheRS onto the human PheRS (HsPheRS)
structure (PDB 3L4G) and mapped the resistance-conferring
mutations for each enzyme on their respective ribbon models
(Fig. 4c). Among these mutations, only TgPheRS[L497I] and
PfPheRS[L550V] are located within the enzyme active site, while
others are close by and likely act allosterically (Fig. 4c). Taken
together, the close relationship between genetic and biochemical
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Fig. 5 Lead compounds from bicyclic azetidine series inhibit growth of ex vivo derived bradyzoites. a Immunoﬂuorescence analysis (IFA) of effects of
compounds on the development of in vitro induced cysts. Bradyzoites were induced at pH 8.2 for 3 days, followed by another 2 days treatment with
compounds at EC90 and 3XEC90. DMSO was used as vehicle control. DBL was used to detect the cyst wall (green) while BAG1 served as bradyzoite
speciﬁc marker (red). Scale bars = 5 µm. b Timeline for monitoring the effect of compounds (Cmpds) on cyst size. c Cysts size was measured for individual
cysts following compound treatment or DMSO control. Data are plotted as means ± SD (n = 20 cysts from 2 independent experiments) and analyzed by
two-sided Kruskal–Wallis test with Dunn’s multiple comparison correction test, **P = 0.0005, ***P = 0.0003, ****P < 0.0001. d Timeline for long term
in vitro induction of bradyzoites followed by plaque assay. Cysts were induced by culture at pH 8.2 for 14 days including treatment with compounds for the
ﬁnal 48 h. e Plaque assay for the effects of compounds on the viability of bradyzoites induced for 14 days. Conditions as shown in (d). Scale bars = 2 mm.
f Quantiﬁcation of plaque numbers in (e). Data were normalized to the average of the DMSO treatment group and plotted as means ± SD for 3
technical replicates from a single experiment. Two-sided Kruskal–Wallis test with Dunn’s multiple comparison correction test, *P = 0.0154, ***P = 0.007.
g Schematic representation of Percoll puriﬁcation of tissue cysts harvested from chronically infected mice and subsequent treatment regimen. Percoll
puriﬁed tissue cysts of ME49-FLuc strain (25 cysts/6 well plate) are treated with acid/pepsin to liberate encysted bradyzoites (10 min, 37 °C) followed by
neutralization with sodium carbonate solution. Liberated bradyzoites are aliquoted into 6 well plates and are either under constant or 4 h washout
treatment conditions and evaluated by plaque assay on day 12–14. h Ex vivo derived bradyzoites were subjected to constant (blue circles) or 4 h washout
(red triangles) at 2.5 μM for each compound. DMSO (vehicle) and pyrimethamine (2.5 μM, growth) were included as controls. Mixed effects analysis with
Dunnett’s multiple comparisons test, ****, P < 0.0001, ***, P = 0.0003. i Treatment of liberated bradyzoites with BRD7929 at EC50: = 0.023 μM,
EC90: = 0.098 μM, 3xEC90: 0.293 μM as indicated (blue circles = constant; red triangles = 4 h washout). Two-way ANOVA with Šidák’s multiple
comparisons test *, P = 0.0299; ****, P < 0.0001, j Inhibition of ex vivo derived bradyzoites by BRD8494 in constant (blue circles) or 4 h washout (red
triangles) treatment conditions at three concentrations: EC50: 0.035 μM; EC90: 0.095 μM; and BRD8494. EC50, EC90 and 3xEC90 values determined using
10-dose–response curve described in Fig. 1. Two-way ANOVA with Šidák’s multiple comparisons test, ****, P < 0.0001. Data represent the mean of three
independent biological replicates each with ≥ 2 technical replicates (n ≥ 6). Solid black line equals the mean and red intervals represent ± SEM. All
statistically signiﬁcant changes are based on comparison to DMSO control for each treatment group. Source data are provided as a Source Data ﬁle.

resistance in T. gondii further corroborates TgPheRS as the
molecular target of BRD7929.
Lead compounds from bicyclic azetidine series inhibit growth
of in vitro differentiated and ex vivo derived bradyzoites. To
determine if bicyclic azetidines could target and eliminate bradyzoites, we developed several assays to monitor their effects
against in vitro bradyzoites using alkaline pH to induce
differentiation24. Initially, we induced bradyzoites during a 3 day
period of culture at pH 8.2 in ambient CO2 during which they
6

convert to stages that express BAG1 and develop a cyst wall that
stains with Dolichos biﬂorus lectin (DBL) (Fig. 5a). Following
3 days induction, compounds were added for an additional 2 days
and then the size of cysts was measured to evaluate continued
growth (Fig. 5b). Treatment with the top 4 compounds
(BRD7929, BRD3444, BRD2987, and BRD8494) at the EC90 or
3xEC90 signiﬁcantly diminished cyst size (Fig. 5c). To further
examine the sensitivity of in vitro derived bradyzoites to bicyclic
azetidines, we extended the in vitro differentiation to 14 days and
treated in vitro derived cysts for the last 48 h of induction
(Fig. 5d). Following treatment, monolayers were disrupted and
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Table 3 Pharmacokinetic parameters of BRD7929 after oral
administration to mouse at repeated dosing of 10 mg/kg
per day with analysis after day 1, 4, and 8.
Parametersa

Day 1

Day 4

Day 8

Cmax (ng/mL)
Tmax (h)
AUC0–24 (hang/mL)
AUC0-inf (hang/mL)
t1/2 (h)
MRT (h)
CL/F (mL/min/kg)
Vd (L/kg)
Kp (Cb/Cp)
Kpu,u (Cb/Cp)

153
18.3
3,187
NA
NA
13.1
NA
NA
169
2.1

330
4.3
6357
27,667
64.6
11.7
7.1
32
211
2.6

207
5.0
4390
19,950
81.3
12
10
62
577
7.2

aThe

value represents the mean.

the cysts were puriﬁed using DBL conjugated to beads followed
by trypsin to liberate the bradyzoites. Puriﬁed bradyzoites were
then cultured on monolayers of HFF cells for 14 days to allow the
formation of plaques in the absence of compounds. Treatment
with the top 4 compounds signiﬁcantly reduced plaque formation
(Fig. 5e,f), indicating that they were effective at reducing the
viability of late stage in vitro derived bradyzoites.
Because in vitro derived bradyzoites do not represent the fully
differentiated forms that occur during chronic infection in vivo25,26,
we also developed an assay to monitor the effects of compounds on
ex vivo bradyzoites isolated from tissue cysts from chronically
infected mice9,27. Cysts were puriﬁed from the brains of chronically
infected mice using Percol gradients, followed by disruption with
pepsin/HCl, neutralization, and treatment in vitro followed by
monitoring growth by plaque assay (Fig. 5g). Treatment with the
top 4 compounds for either 4 h followed by washout or under
constant treatment conditions almost completely eliminated growth
when used at high concentrations (i.e. 2.5 μM) (Fig. 5h). To further
explore the sensitivity of ex vivo bradyzoites to treatment,
we assayed BRD7929 (Fig. 5i) and BRD8494 (Fig. 5j) at EC50,
EC90, and 3×EC90 concentrations based on tachyzoite growth assays
(Table S1). At the EC50, BRD7929 only partially reduced growth
compared to vehicle controls (DMSO) (Fig. 5i), indicating that
bradyzoites are slightly less susceptible than tachyzoites. Increasing
BRD7929 to the EC90 or 3×EC90 resulted in 93% and 99% growth
inhibition during constant treatment and this effect was sustained
following washout after short-term treatment at 3×EC90 (Fig. 5i).
Constant treatment with BRD8494 did not inhibit the growth of
liberated bradyzoites at the EC50, yet both higher concentrations
nearly eliminated growth under constant treatment (Fig. 5j).
Treatment followed by washout for BRD8494 failed to inhibit
growth regardless of concentration (Fig. 5j). Collectively, the dosedependent activity of bicyclic azetidines against in vitro differentiated and ex vivo derived bradyzoites demonstrate that these
compounds are capable of acting on both acute and chronic stages
of T. gondii.
Pharmacokinetics studies. Previous pharmacokinetics (PK) studies of BRD7929 in mouse found that it has good oral bioavailability (80%) and a very stable half-life in plasma following a
single administration15. Therefore, we chose to focus on this
compound for further in vivo studies. In order to examine the PK
properties over a longer time frame, we started with conditions
that had previously been used (i.e. 10 mg/kg) for single-dose
studies and performed a repeated dosing study by administering
BRD7929 at 10 mg/kg p.o. once a day for eight days with interval
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sampling during days 1, 4, and 8. Consistent with previous
ﬁndings, the compound reached steady state levels in plasma
during the ﬁrst 24 h with modest Cmax and AUC values (Table 3)
and then remained relatively constant during the 8 day period,
albeit with a minor increase during day 4 (Fig. 6a). Compound
BRD7929 is highly hydrophobic and not surprising, it showed
high binding to plasma proteins (96.01%) and brain tissues
(99.95%). In order to estimate the levels of free compound in
plasma and brain we plotted the concentrations of unbound
compound vs. time and compared them to values for growth
inhibition obtained in vitro. Comparison of these curves indicates
that the concentrations achieved in plasma were well below the
EC50 values (Fig. 6a). Because toxoplasmosis is a major concern
for CNS infection, we were also interested in the ability of
BRD7929 to reach the brain and accumulate there over time.
Sampling of brain tissue indicated that BRD7929 was readily
absorbed in brain tissue and in fact accumulated in tissue relative
to plasma, likely due to a high volume of distribution (Vd)
(Table 3). Comparison of the unbound concentrations in brain vs.
plasma (i.e. Kp u,u) indicated that BRD7929 is concentrated ~ 2–7
fold in brain vs. plasma from days 1 to 8 (Table 3), indicating that
it has a favorable proﬁle for CNS indications. Plotting the free
concentrations achieved in plasma indicated that the compound
remained below the EC50 for most of the duration (Fig. 6a). In
contrast, the free levels of compound in the brain exceeded the
EC50 and nearly reached the EC90 by day 8 (Fig. 6a). We also
investigated higher doses of oral administration of BRD7929 but
found that increasing the dose to 30 mg/kg did not lead to a
proportional increase in plasma levels and instead resulted to
overt signs of toxicity. Although the basis for this adverse effect
was not investigated further, we decided to adopt the dose of
10 mg/kg for efﬁcacy studies.
Compound BRD7929 protects immunocompromised mice
from acute and chronic infection. To further evaluate the
potency of bicyclic azetidines for multistage inhibition of T.
gondii growth, we utilized interferon-gamma receptor knockout
mice (Ifngr1−/−), which are completely susceptible to T. gondii
infection because they cannot mount an effective immune
response28. To determine whether the bicyclic azetidine BRD7929
could protect from T. gondii oral challenge, we infected Ifngr1−/−
mice with freshly isolated tissue cysts (type II, ME49-FLuc strain)
by oral gavage and allowed 48 h post-challenge before starting
three parallel treatment regimens (Fig. 6b). Mice were treated
once a day (QD) by oral gavage with BRD7929 for 10 days or
20 days (Fig. 6c) at 10 mg/kg. We compared these treatments to
sulfadiazine (sulfa, 0.25 g/L in drinking water)29, which prevents
death from acute infection, but allows the development of bradyzoite containing tissue cysts. Treatment with BRD7929 for both
10 days (mean survival = 16.5 days) and 20 days (mean survival
= 21 days) greatly extended the survival time vs. sulfadiazine
alone (mean survival = 10 days) (Fig. 6c). Moreover, treatment
with BRD7929 prevented death in 3 of 8 mice when the treatment
was extended to 20 days (Fig. 6c), indicating a longer treatment
window is signiﬁcantly more effective in preventing the establishment of latency and/or reactivation. Importantly, surviving
mice were seropositive indicating they had become infected
(Fig. S5). As these animals are profoundly immunocompromised,
their survival for this length of time after completion of treatment
suggested that their infections were cured. To conﬁrm that surviving animals were not harboring infectious parasites, they were
sacriﬁced, the brain removed, homogenized, and gavaged into
recipient naïve Ifngr1−/− mice that were left untreated and
monitored for 20 days. All recipient mice survived and remained
seronegative (Fig. S5), conﬁrming that treatment had resulted in
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Fig. 6 BRD7929 accumulates in the brain and protects Ifngr1−/− mice
from oral challenge with tissue cysts and prevents establishment of
chronic infection. a Repeated dose PK studies of BRD7929 in mouse.
Compounds were administered daily p.o. at 10 mg/kg for 8 days with
sampling at 1, 3, 7, and 24 h on day 1, 4, and 8 (n = 3 animals per group,
repeated twice, with one experiment plotted). Values plotted are means ±
S.D. were based on unbound fractions in plasma or brain. Values for EC50,
EC90, and 3 x EC90 were based on in vitro studies with tachyzoites.
b Schematic of oral challenge protection model for treatment of
toxoplasmosis. Ifngr1−/− mice were infected with the ME49-FLuc strain.
Two days later mice were divided into three treatment cohorts: (1)
sulfadiazine (sulfa, 0.25 g/L in drinking water, n = 6 (3 male, 3 female),
black arrow) for 20 days, (2) BRD7929 at 10 mg/kg p.o. once per day for
10 days (red arrow, n = 8 (4 male, 4 female)) or (3) BRD7929 at 10 mg/kg
p.o. once per day for 20 days (blue arrow, n = 8 (4 male, 4 female)). Mice
were then monitored for reactivation (green arrow) by survival and weight
loss. c Surviving mice were monitored for at least 29 days post-treatment.
Mice treated for 20 days with BD7929 survived signiﬁcantly longer than
sulfadiazine mice (*, P = 0.0487, Mantel-Cox test). † = two surviving mice
from the 10-day cohort reached day 29, however, one succumbed to
infection on day 33. All surviving mice were positive for T. gondii infection
by ELISA and veriﬁed to be cured by bioassay into naïve recipient mice
(Fig. S5). d Diagram of reactivation model for chronic toxoplasmosis
including treatment regimen. Ifngr1−/− mice were infected with the ME49FLuc strain by oral gavage. Animals were placed on sulfadiazine from day
2–20 (0.25 g/L in drinking water). Two days after removal of sulfadiazine
animals were treated with vehicle (black, n = 5 (2 male, 3 female)) or once
a day with BRD7929 at 10 mg/kg p.o. for 16 days (red line, n = 7 (4 male, 3
female)). Reactivation of chronic infection (green arrow) was monitored for
at least 20 days post-treatment. e Control mice (vehicle, black) quickly
succumb to recrudescent infection within 10 days. Mice treated with
BRD7929 survived signiﬁcantly longer, including one animal that was
veriﬁed to be cured by bioassay into naïve recipient mice (***, P = 0.0003,
Mantel-Cox test). Images of mice created with BioRender. Source data are
provided as a Source Data ﬁle.

cure in the donor animal. Collectively, these ﬁndings indicate that
BRD7929 prevented death during acute infection and either
prevented tissue cysts from forming or eliminated them during
chronic infection. Overall, 4 of 16 animals were cured by treatment with BRD7929.
To further understand the potential of BRD7929 as a
therapeutic for the treatment for chronic toxoplasmosis, we
8

tested whether treatment could prevent reactivation of latent
infection using the Ifngr1−/− mouse model of chronic infection
(Fig. 6d)27. We infected Ifngr1−/− mice with tissue cysts by oral
gavage (type II, ME49-FLuc) and treated with sulfadiazine for
20 days starting 2 days post-infection to allow for the establishment of chronic infection and prevent death by acute infection.
Because sulfadiazine has no activity against tissue cysts,
discontinuation of treatment results in reactivation of chronic
infection and re-emergence of tachyzoite proliferation leading to
death in 7–10 days28. Following removal of sulfadiazine (2 days),
animals were treated QD by oral gavage for 16 days with
BRD7929 (10 mg/kg) or vehicle control (Fig. 6d). Without
sulfadiazine, control mice rapidly succumbed to recrudescent
infection, whereas animals receiving BRD7929 had a delayed
onset of death, including 1 of 6 animals who survived >20 days
post-treatment window (Fig. 6e). This sole surviving animal was
seropositive (Fig. S5a), and subsequent bioassay of brain
homogenate into a naive recipient Ifngr1−/− mouse failed to
detect any residual infection. Collectively, these ﬁndings indicate
that this surviving animal was cured of chronic infection by
treatment with BRD7929.
Discussion
Current therapies for toxoplasmosis are effective at controlling
acute infection caused by proliferating tachyzoites while having
minimal impact on chronic infection caused by semi-dormant
bradyzoites8. To identify new inhibitors that might address this
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critical need, we evaluated bicyclic azetidines that have previously
been shown to be multistage inhibitors of apicomplexan
parasites15,16. There was a strong correlation between the potency
of bicyclic azetidines in inhibiting growth of T. gondii, P. falciparum, and C. parvum, suggesting a common mechanism of
action. Comparison of the inhibitory activity of bicyclic azetidines
against puriﬁed enzymes revealed they are potent and selective
inhibitors of T. gondii PheRS relative to the human counterpart.
Moreover, mutational studies, based both on directed point
mutations and evolved resistance, identiﬁed PheRS as the primary
target of bicyclic azetidines in T. gondii. The lead compound in
this series BRD7929 demonstrated good bioavailability and concentration in the CNS and was able to control acute infection as
well as partially prevent the establishment and reactivation of
chronic infection in a relevant mouse model. Collectively, these
studies indicate that PheRS is essential, druggable, and provides
an excellent target for further studies to optimize inhibitors for
control of acute and chronic toxoplasmosis. Additionally, unlike
many other inhibitors that show more selective proﬁles30, bicyclic
azetidines have broad efﬁcacy across the Apicomplexa as shown
here for T. gondii and N. caninum and in previous studies on
Cryptosporidium16 and Plasmodium15,18.
The current standard of care for toxoplasmosis is based on
inhibition of the folate pathway using a combination of pyrimethamine with a sulfa drug (e.g. sulfadiazine or sulfamethoxazole)
that act synergistically to block DNA/RNA synthesis and prevent
replication8. Although effective in controlling acute infection, there
are issues with allergic reactions to the sulfa component, bone
marrow suppression that requires co-administration of leucovorin
(folinic acid), and adverse reactions to pyrimethamine31. These
issues are particularly problematic where long-term treatment is
required to control disease such as in immunocompromised
patients8 or in cases of recurrent ocular infection, which is common
in South America32. Additionally, this combination treatment,
while synergistic in controlling tachyzoite proliferation, is unable to
eradicate chronic infection, presumably because bradyzoites divide
slowly and asynchronously and hence they are not susceptible to
the inhibitory action of anti-folates8. Other antibiotics that also
show efﬁcacy, including tetracycline, clindamycin, azithromycin,
and related analogs, also only act against the actively proliferating
tachyzoite form8. In contrast, atovaquone29,33 and quinolones34,35,
both of which inhibit the cytochrome bc1 complex of the mitochondria, show some efﬁcacy in reducing the burden of tissue cysts
in vivo. Unfortunately, atovaquone is limited by treatment
failures36–38 that may result from high-frequency emergence of
drug resistance as shown in laboratory studies39,40. Although quinolones suffer from limited solubility that hampers bioavailability,
this problem has been partially resolved using esteriﬁed prodrugs35
or tetrahydroquinones, which have a similar molecular target41.
Notably, neither of these compounds is able to completely eradicate
chronic infection, similar to other recently described compounds
that show efﬁcacy in the mouse model of toxoplasmosis42. Other
recent studies show that modulation of immune responses using the
TLR7 agonist imiquimod can reduce chronic infection and suppress
subsequent infection by treated bradyzoites in an immunocompetent mouse model43. Using a more stringent model for reactivation
of chronic infection, it was shown that ATP mimetics that speciﬁcally inhibit calcium-dependent protein kinase 1 (CPKD1) both
reduce the burden of chronic infection44 and prevent reactivation in
an immunocompromised mouse model of toxoplasmosis27,45.
Importantly, in this chronic model of reactivation, compounds
must both control tachyzoite growth and eliminate all residual cysts
to allow survival of the animal, thus providing a rigorous endpoint
to monitor radical cure.
Apicomplexan parasites contain three genes encoding phenylalanine tRNA synthase that are compartmentalized in the
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mitochondria, apicoplast, and cytosol where they independently
participate in protein translation46. Previous studies have shown
that bicyclic azetidines are potent and speciﬁc inhibitors of the
alpha subunit of the cytosolic PheRS from P. falciparum15 and C.
parvum16. Our current studies extend these ﬁndings to demonstrate that bicyclic azetidines are also potent and selective inhibitors of cytosolic T. gondii PheRS. The core azetidine ring in the
bicyclic azetidines contains three chiral centers, resulting in eight
topologically distinct stereoisomers that exhibit very different
geometries. Comparison of these eight stereoisomers revealed that
the stereochemical speciﬁcity of T. gondii growth inhibition by
bicyclic azetidines was highly similar to that reported previously
for P. falciparum15. These ﬁndings suggest that the binding mode
of bicyclic azetidines is highly similar among these two species,
although it is evidently much different from HsPheRS resulting in
>500-fold selectivity. Homology modeling of the PfPheRS and
TgPheRS enzymes predicts a high degree of similarity that
allowed us to compare sites that resulted in resistance to bicyclic
azetidines. In this regard, position 497 in TgPheRS, which corresponds to position 550 in PfPheRS, is highly informative as
the mutant TgPheRS[L497V], similar to that seen in resistant
P. falciparum15, renders T. gondii highly resistant to inhibition by
bicyclic azetidines like BRD7929. A similar mutation of
CpPheRS[L482V] in C. parvum results in resistance to bicyclic
azetidines, emphasizing the conserved nature of this binding
interaction in compound potency16. Additionally, selection of
resistance mutations in T. gondii resulted in a similar change in
TgPheRS[L497I], which also resulted in high-level resistance. Additional point mutations in TgPheRS that were identiﬁed by wholegenome sequencing of resistant pools of parasites resulted in much
lower levels of resistance when introduced as single mutations or in
combination in wild-type parasites. Our studies were performed in
a type I strain due to available genetic tools that facilitate the
introduction of point mutations needed to validate the function of
individual residues. However, we expect that similar observations
would be made using other strain types as there are no polymorphisms in the PheRS gene among commonly used lab strains
and the potency of compounds in inhibiting strains from widely
different lineages was highly similar. Despite the fact that resistance
mutations were readily obtained by a prolonged passage in vitro,
their occurrence in vivo is likely to be less common given that
parasite burdens rarely reach high levels during chronic infection
and there is the limited human-to-human transmission.
Our ﬁndings demonstrate that bicyclic azetidines are potent
against tachyzoites at low nM levels and treatment of bradyzoites
in vitro at EC90 or 3xEC90 concentrations results in almost
complete killing, consistent with the potent and irreversible
effects of these inhibitors against other apicomplexans15–17.
Although it is clear that bicyclic azetidines targeting PheRS provide broad-spectrum inhibition of apicomplexan growth, the
conservation of this target also complicates the goal of designing
compounds speciﬁc to each parasite. Further structural and
medicinal chemistry efforts may uncover speciﬁcity in the binding pocket that could be exploited for selectivity. Alternatively, it
may be possible to take advantage of the tissue compartmentalization to drive speciﬁcity. Compounds that are effective against
the asexual stages of P. falciparum would likely beneﬁt from
prolonged plasma exposure15. In contrast, studies of inhibitors of
PI(4)K in C. parvum have emphasized the importance of lower
bioavailability to maintain intestinal luminal concentrations
without raising the risk of systemic exposure47, although PheRS
inhibitors like BRD7929, which has good oral bioavailability, are
also effective in this model16. Finally, since the target organ for
chronic T. gondii infection is the brain and muscle, compounds
with CNS penetration and high tissue distribution may be used to
preferentially target this organism.
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Compound BRD7929 exhibits several highly desirable properties as a lead compound for treatment of toxoplasmosis. It has
good oral bioavailability, a long half-life, high volume of tissue
distribution, good potency, and a selective proﬁle. These properties combined to provide excellent protection from acute
infection and partial protection from chronic reactivation in an
immunocompromised mouse model of toxoplasmosis. However,
there are several limitations with BRD7929 that currently limit its
utility for further in vivo studies. High protein binding results in
low exposure of free compound and combined with the high
volume of tissue distribution may contribute to lack of increased
plasma exposure with higher dosing in vivo. In preliminary trials,
increased repeated dosing with BRD7929 also resulted in adverse
symptoms, which may be related to its previously described
effects on ion channels15. Finally, free concentrations of BRD7929
in the brain tissue exceeded the EC50 value but did not quite reach
the EC90 level, which likely resulted in the observed partial protection from chronic infection. In this regard, the somewhat
higher toxicity for bicyclic azetidines for monocytic and neuronal
lineages highlights an additional liability of the current lead.
Further medicinal chemistry efforts to increase tissue exposure
without such adverse effects will be needed to fully explore the
pharmacodynamic properties and to identify more potent leads
for eradicating chronic T. gondii infection. Provided improved
leads can be identiﬁed, it would be important to extend the
ﬁndings reported here to test challenge with different life cycle
stages such as oocysts, to monitor the efﬁcacy of treatment on
development and shedding of sexual stages, and to examine other
disease models including ocular and congenital infection.
Methods
Small-molecule synthesis. Molecules employed in this study were prepared using
procedures derived from previously published methods15,16. Speciﬁc synthetic
schemes, procedures, and analytical data are available in the Supporting Information (Fig. S1).
Animals. Ifngr1−/− (B6.129S7-Ifngr1 tm1Agt /J) and CBA/J mice were purchased
from Jackson Laboratory and bred locally at Washington University. Animal
studies were conducted according to the U.S. Public Health Service policy on
human care and use of laboratory animals. Animals were maintained in facilities
approved by the Association for Assessment and Accreditation of Laboratory
Animal Care. Studies were approved by Division of Comparative Medicine,
Washington University. Sex and age matched mice between 8 and 12 weeks of age
were used to perform experiments. Animals were maintained on a 12:12 light cycle,
room temperature maintained at 70℉ ± 2℉, and room humidity maintained at
50% ± 20%.
Parasite strains and host cell culture. Toxoplasma gondii strains
RHΔhxgprtΔku80 (RHΔΔ)22, RH-FLuc (type I)48, and ME49-FLuc (type II)19, were
previously reported. New transgenic lines created here are found in Table S2. The
Neospora caninum strain expressing β-galactosidase was described previously21.
Tachyzoites from T. gondii and N. caninum were maintained by serial passage in
conﬂuent monolayers of human foreskin ﬁbroblasts (HFF) as previously
described21,30. HFF and parasite cultures were grown in 10% DMEM (DMEM
supplemented with glutamine (10 mM), gentamycin (10 μg/mL, and 10% fetal
bovine serum) incubated at 37 °C with 5% CO2 and were veriﬁed mycoplasma free
by the e-Myco Plus kit (Intron Biotechnology).
Genome editing and parasite transfection. In vitro cultures of HFF cells containing mature vacuoles were scraped, passaged through 23 g blunt end needles,
and ﬁltered using 3 micron ﬁlters. Puriﬁed parasites were resuspended in 350 μL of
cytomix plus49 and combined in a BTX 4 mm gap cuvette with 30 μL of PCR
ampliﬁed templates corresponding to mutations of interest and 10 μg of
pSAG1:Cas9-GFP U6:sgTgPheRS[mut] (in 20 μL, 400 μL total volume, see Supplementary Data 1 for sgRNA sequences) prior to electroporation using a BTX
ETM 830 electroporator. Ampliﬁed templates for TgPheRS mutations were generated from gBlocks (Integrated DNA Technologies, Coralville, IA, USA) that
contain a BclI restriction site that replaces the PAM sequence to protect the repair
template from being cut by Cas9. At 16 h post-transfection, transgenic parasites
expressing pSAG1:Cas9-GFP were sorted on a Sony SH800 FACS sorter directly
into 96-well plates. Single clones containing TgPheRS[mut] were identiﬁed by
amplifying a ~500 bp PCR fragment around introduced mutation followed by
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digestion using BclI (New England Biolabs) BclI sensitive clones were expanded
and the locus was Sanger sequenced to verify incorporation of each independent
mutation. To generate ﬁreﬂy luciferase (FLuc) expressing strains, freshly harvested
parasites were combined with 20 μg of pTUB-FLUC DHFR ﬂox plasmid and 10 μg
of pSAG1:Cas9-GFP U6:sgUPRT50 (in 50 μL cytomix plus) and transformed by
electroporation as described above. Parasites were allowed to recover overnight
followed by sequential selection with pyrimethamine (1.0 μM) and
5-ﬂurodeoxyuracil (FUDR, 10 μM), as described previously48. Stable clones were
isolated by limiting dilution and a clone from each genetic background selected
based on high luciferase activity (Table 1).
Parasite growth and EC50 determination assays. All assays were carried out in a
96-well plate format containing conﬂuent HFF monolayers to support parasite
growth. To avoid edge effects, only the inner 60 wells of each plate were used. All
compounds described were provided by the Broad Institute as 10 mM stocks in
100% DMSO and stored at −80 °C prior to use. Pyrimethamine (Sigma-Aldrich)
was prepared as 5 mM stock in 100% DMSO and stored at −20 °C prior to use.
Tachyzoite lytic assay. Parasite growth on HFF monolayers was monitored using a
96-well plate-based lytic assay modiﬁed from a previously described protocol23.
BRD7929 was diluted in 10% DMEM media to create a 20 μM solution that was
then serially diluted 1:3 in DMEM across each 96-well plate to generate a 10-dose
series of BRD7929 at 2X ﬁnal concentration (in 100 μL vol). Freshly harvested
parasites (7.5 × 104 /well) were added to each well (in 100uL volume) to reach the
ﬁnal concentration range (10 μM to 0.0005 μM, 200 μL/well, 0.1% DMSO). Plates
were incubated for 72 h at 37 °C then culture medium was aspirated and monolayers were ﬁxed with 100% ethanol (ETOH) for 5 min at room temperature (RT).
After rinsing with water, wells were stained with 0.1% crystal violet solution for
10 min at RT. Plates were rinsed with water, air dried, and absorption quantiﬁed on
the Cytation 3 multi-mode imager at 570 nm wavelength. % parasite growth was
calculated as 100−[(OD value for infected cultures at each concentration of
compound/average OD value for no compound and no parasite infection) × 100].
EC50 values were calculated based on the mean of three biological replicates with
each replicate containing two technical replicates.
Luciferase-based tachyzoite growth assay. Luciferase assays were performed using
the inner 60 wells of a clear bottom, white 96-well plate (Costar) to avoid well-towell interference as previously detailed11,30. Compounds were diluted to generate a
3-fold dilution series as described above. Freshly harvested ME49-FLuc parasites (5
× 103) were added to each well (in 100 μL volume) to yield 1x ﬁnal compound
concentration (200 μL/well total volume, 0.1% DMSO in 10% DMEM medium).
Plates were incubated for 72 h at 37 °C prior to analysis using the Luciferase Assay
System protocol (Promega) and described11,30. Brieﬂy, culture media was replaced
with 30 μL of 1x Cell Culture Lysis Reagent (Promega) and incubated for 10 min at
RT. Following cell lysis, 100 μL of LAR reagent was added to each well and
luciferase activity measured using a Beckman Coulter instrument. All liquid
handling steps (compound serial dilution, media exchange and luciferase steps)
were completed on a Dual Pod Biomek FX driven by the SAMI EX software system
to ensure efﬁcient and uniform execution of assays across all replicates (HighThroughput Screening Center, Washington University School of Medicine).
Neospora caninum β-galactosidase assay. β-galactosidase assays were conducted
using tissue culture grade 96-well plates (TPP) containing conﬂuent monolayers of
HFF cells. A 10-point compound dilution series (2-fold) for each compound was
generated as described above (2X concentration, 0.1% ﬁnal DMSO). Growth of the
N. caninum strain expressing lacZ was monitoring using a β-galactosidase (β-gal)
assay as described in21 with the following modiﬁcations. N. caninum lacZ
expressing parasites (1 × 103) were added (in 100 μL volume) into 96-well plates
containing HFF monolayers to reach ﬁnal compound concentration (5.0 μM to
0.002 μM in 200 μL total volume). Plates were incubated at 37 °C, 5% CO2 for 72 h
prior to completing β-gal assay as previously described23,27,51. Brieﬂy, parasite
containing monolayers were lysed with 1.0% Triton X-100 and β-gal activity
determined by adding 1 mM chlorophenolred-β-D-galactopyranoside followed by
monitoring absorption at 570 nM on a Cytation 3 multi-mode imager (BioTek), as
described51.
Cloning of PheRS and generation of mutants. For expression and puriﬁcation of
TgPheRS (Toxoplasma gondii cytoplasmic-Phenylalanine tRNA synthetase)
enzyme, the amino acid sequence for the α (TGME49_234505) and β
(TGME49_306960) subunits were retrieved from the ToxoDB (https://toxodb.org).
The genes were synthesized and codon optimized by Geneart for expression in E.
coli cells. The gene for α-subunit was cloned into the pETM11 and gene for βsubunit was cloned in pETM20 expression vectors employing Nco1 and Kpn1
restriction sites. Both the subunits (α and β) were co-transformed in E. coli BL-21
competent cells. Subsequent resistance conferring mutations were introduced into
pETM11-TgPheRS plasmid using a site directed mutagenesis approach and
assembled using the NEBuilder HiFi DNA Assembly kit according to manufacturer’s protocol. All pETM11-TgPhers[mut] plasmids were Sanger sequenced to
verify presence of mutation prior to use. See Table S3 for primer information.
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Similarly, for HsPheRS (Homo sapiens cytoplasmic- Phenylalanine tRNA synthetase) enzyme, the full-length sequence for α (UniProtKB - Q9Y285 (SYFA_HUMAN)) and β (UniProtKB - Q9BR63 (Q9BR63_HUMAN)) subunits were retrieved
using their uniport IDs. Both the subunits of the HsPheRS protein were synthesized
by Geneart and co-transformed in E. coli B834 cells.
Protein expression and puriﬁcation. For puriﬁcation of both wild type and
mutant TgPheRS, E.coli cultures were grown at 37 °C to an OD600 of 0.6–0.8.
recombinant protein expression was induced by the addition of 0.6 mM isopropyl
β-d-1-thiogalactopyranoside (IPTG) at 18 °C. After 18–20 h post-induction, the
cells were harvested by centrifugation at 5,000 g for 20 min, resuspended in binding
buffer (50 mM Tris–HCl (pH 8), 200 mM NaCl, 4 mM β-mercaptoethanol (βMe),
10% (v/v) glycerol, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF) and 0.1 mg/mL
lysozyme), and lysed using sonication. The lysed cells were then centrifuged at
20,000 g for 45 min and the cleared soluble protein lysate was loaded on a prepacked Ni-NTA column (GE Healthcare). Proteins which bound the Ni-NTA were
washed with 20 column volumes of binding buffer supplemented with 20 mM
imidazole to remove impurities. Bound protein was eluted using a concentration
gradient of imidazole from 0 to 1 M in elution buffer (80 mM NaCl, 50 mM
Tris–HCl (pH 8), 4 mM β-mercaptoethanol, 10% (v/v) glycerol, 1 M imidazole,
using AKTA-FPLC system (GE healthcare)). The fractions which contained puriﬁed protein were pooled together and concentrated using 30-kDa cut-off centrifugal devices (Millipore) followed by size exclusion chromatography using the
GE HiLoad 60/600 Superdex column in a buffer containing 50 mM HEPES (pH 8),
200 mM NaCl, 4 mM β-mercaptoethanol, 1 mM MgCl2. Purity of the eluted fractions was veriﬁed on a SDS PAGE gel, fractions pooled together and stored at
−80 °C until further use.
Enzyme assay. The enzyme-inhibition assays for the recombinant wild-type
TgPheRS, TgPheRS mutants, and HsPheRS proteins were performed as per earlier
published reports15,18,46. Brieﬂy, the assays were performed using malachite green
based aminoacylation assay that determined the ﬁrst step of the reaction by
measuring the amount of phosphate released. All the enzymatic assays were performed in clear ﬂat bottom 96-well plates at 37 °C with 100 nM recombinant
PheRS enzymes in a total volume of 50 μL. The assays were done in a standard
aminoacylation buffer comprising 50 mM MgCl2, 150 mM NaCl, 30 mM HEPES
(pH 7.5), 30 mM KCl, 1 mM DTT. The assays were initiated by adding 50 µM Lphenylalanine, 100 µM ATP and 2 U/mL E. coli inorganic pyrophosphatase (NEB).
For determination of IC50 values a 10-fold dilution of BRD7929 was done in
aminoacylation assay buffer starting with 100 μM to ﬁnal concentration of
0.000001 μM and the reaction mixture was incubated for 2 h at 37 °C. The reaction
was stopped using malachite green stop solution and incubated at room temperature for 5 min. Enzyme activity was quantiﬁed using SpectraMax M2 (Molecular Devices) at 620 nm. MBP (maltose binding protein) was used a negative
control for protein binding the reaction mixture. All the experiments were repeated
three independent times with internal triplicates.
TgPheRS homology modeling. The TgPheRS (ToxoDB Gene ID:
TGME49_234505) and PfPheRS (Plasmodium falciparum cytoplasmic- Phenylalanine aminoacyl tRNA synthetase) (PlasmoDB gene ID: PF3D7_0109800)
homology model was built using Prime (Schrödinger Release 2015-2: Prime, version 4.0, Schrödinger)52,53 with HsPheRS PDB 3L4G as a template. HsPheRS was
chosen as template based on the identity and highest sequence similarity determined via PSI-BLAST. Cluster Omega was used to make the target-template
alignment54 using the EMBL server (https://www.ebi.ac.uk/Tools/msa/clustalo/)
and the model was built and reﬁned using the default settings in Prime. Figures for
display were prepared with Chimera55. The TtPheRS-L-Phe-AMP-tRNA (PDB
2IY5 structure was used to mark the amino acid binding site (L-Phe), ATP site and
tRNA binding site on the PfPheRS and TgPheRS homology models.
Evolved resistance to BRD7929 in T. gondii tachyzoites and identiﬁcation of resistance conferring mutations. Tachyzoites of the strain RH-FLuc (clone B2)48 were
serially passaged at sub-lethal concentrations of BRD7929 (starting concentrations
0.1 μM (~3X EC50). Concentrations of BRD7929 were increased step-wise (0.1 μM
to 0.5 μM to 1.0 μM to 5.0 μM, respectively) when parasites underwent normal lytic
growth on 48–72 h cycle for one to two weeks. Genomic DNA (gDNA) was isolated
from resistant parasites from pool 1 (1.0 μM ﬁnal concentration) and pool 2 (5 μM
ﬁnal concentration) using a DNeasy Blood and Tissue DNA isolation kit (Qiagen).
Following gDNA puriﬁcation, 1–3 μg of gDNA from RH-FLuc (parent), and each
of the BRD7929 resistant pools was submitted to the Genome Technology Access
Center at Washington University for whole genome sequencing (WGS) on the
Illumina NovaSeq6000 platform. Sequencing analysis was completed using CLC
Genomics Workbench (v20, Qiagen) by applying the Resequencing Analysis using
Tracks function and mapping pool 1 and pool 2 genomes against the RH-FLuc
parent to identify genome level mutations (using default parameters).
In vitro tachyzoite growth assays. Parasite growth on HFF monolayers was monitored by plaque formation using a 6 well plate assay. Freshly harvested parasites
(200/well) were added to each well. Plates were incubated for 7 day at 37 °C in
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DMEM-10%FBS, then the culture medium was aspirated and monolayers were
ﬁxed with 100% ethanol for 5 min at room temperature. After rinsing with water,
wells were stained with 0.1% crystal violet solution for 10 min at room temperature.
Plates were rinsed with water, air dried, and plaques were quantiﬁed on a Zeiss
AxioObserver microscope equipped with a 2.5x objective. Wells were imaged using
a ChemiDoc Imager (BioRad) equipped with white light conversion screen and
plaques area were measured using ImageJ software. Data were generated based on
two biological replicates with each replicate containing three technical replicates.
Parasite growth on HFF monolayers was monitored using a lytic growth assay in
96-well plates. Freshly harvested parasites (2 × 104 /well) were added to each well in
nd
2 column and then serially diluted 1:2 in media to generate a 10-step dilution series.
Plates were incubated in DMEM-10% FBS culture medium for 72 h at 37 °C then
culture medium was aspirated, and monolayers were ﬁxed with 100% ethanol for
5 min at room temperature. After rinsing with water, wells were stained with 0.1%
crystal violet solution for 10 min at room temperature. Plates were rinsed with water,
air dried, and absorption quantiﬁed on the Cytation 3 multi-mode imager at 570 nm.
The growth curves were generated in Prism (GraphPad) based on the mean of two
biological replicates with each replicate containing three technical replicates.
PK studies. BRD7929 was dosed orally at 10 mg/kg as a suspension in 10% ethanol,
4% Tween 80 and 86% saline to female CD1 mice with three mice per dosing
group. All mice were fed prior to dosing. After dosing, 200 uL of blood was
collected at predetermined time points (pre, 1, 3, 7, 24 h). Blood samples were
processed for plasma by centrifugation at approximately 4 °C, 4,500 g for 15 min
within min of collection. Plasma samples were stored in polypropylene tubes, quick
frozen over dry ice and kept at −70 ± 10 °C until LC/MS/MS analysis. Plasma
concentration versus time data was analyzed by non-compartmental approaches
using the Phoenix WinNonlin 6.3 software program. Brain tissue samples were
taken at day 1, 4, and 8. Tissue samples were processed by centrifugation at
approximately 10 °C, 17,000 g for 30 min within 30 min of collection.
In vitro bradyzoite growth assays. To monitor the effects of compounds on early
bradyzoite differentiation, ME49-Fluc tachyzoites were inoculated onto HFF
monolayers grown on coverslips in 24-well plates and allowed infect during a 2 h
incubation in 3% DMEM (DMEM containing glutamine (10 mM), gentamycin (10
μg/mL,) and 3% FBS) at 37°C, 5% CO2. The medium was replaced with RPMI 1640
pH 8.2 and cells were cultured in ambient CO2 at 37°C for 3 days to induce
bradyzoites. Monolayers were treated with compounds at EC90 or 3XEC90 for
another 2 days during culture in RPMI 1640 pH 8.2 at ambient CO2 and 37°C.
Samples were ﬁxed and stained using biotinylated Dolichos biﬂorus lectin (DBL)
(Vector Laboratories (#B-1035-5) 1,1,000) followed by Alexa Fluor 488 streptavidin
(Thermo Fischer (#S11223) 1:1,000 dilution) and mouse mAb 8.25.8 anti-BAG1
(from Dr. Louis Wiess) (1:1,100)56 followed by goat anti-mouse IgG conjugated to
Alexa Fluor 568 (Thermo Fischer (#A-1104) 1:1,000). Samples were analyzed using
a Zeiss AxioObserver Z1 equipped with Colibri LED illumination using a 40x EC
Plan-Neoﬂuar objective (N.A. 1.3) and images were captured using an ORCA-ER
digital camera operated using ZEN v3.3 (Carl Zeiss). Cyst size was determined by
measuring the area deﬁned by the perimeter of the cyst wall as measured in
microns.
To monitor the effects of compounds on more mature in vitro derived bradyzoites,
ME49-Fluc tachyzoites were inoculated onto HFF monolayers grown in T252 ﬂasks
and bradyzoites were induced for 12 days in RPMI 1640 pH 8.2 at ambient CO2 and
37°C. Cultures were then treated with compounds at EC90 or 3XEC90 for another
2 days. At the end of 14 days, monolayers were scraped and passed through a 23 g
needle to liberate cysts, followed by centrifugation (400 × g, 10 min, 4 °C). Pellets were
resuspended with PearceTM streptavidin magnetic beads (Thermo Fisher) precoupled with biotinylated DBL (Vector laboratories) and incubated for 1 h at 4 °C.
Beads were collected and washed twice using a magnetic stand, followed by treatment
with 0.25 mg/ml trypsin for 10 min to liberate bradyzoites. Released bradyzoites were
collected from the supernatant and counted using a hemocytometer. Bradyzoites were
inoculated onto 6-well plates conﬂuent with HFF monolayers and cultured for
14 days, followed by ethanol ﬁxation and staining with 0.01% crystal violet. Plaques or
foci of infection were imaged using an Axiovert 100 microscope equipped with an
AxioCam color camera and analyzed by ImageJ.
Ex vivo bradyzoite treatment assays. The brains from CBA/J mice chronically
infected with the ME49-FLuc strain were harvested, homogenized, and tissue cysts
isolated on Percoll gradients, as described previously9,27. Following isolation,
puriﬁed tissue cysts were treated with acid-pepsin solution (170 nM sodium
chloride (NaCl), 60 mM hydrochloric acid (HCl) and freshly made pepsin (0.1 mg/
mL in 1xPBS) for 10 min at 37 °C. Following acid-pepsin treatment and addition of
neutralization buffer (94 mM sodium carbonate (Na2CO3), liberated bradyzoites
were equally distributed into 6-well plates with 5 mL culture media containing
compounds or vehicle control (0.1–0.2% DMSO ﬁnal concentration). Plates were
incubated undisturbed for 12–14 days followed by ﬁxation in 100% ethanol
(ETOH) for 5 min at RT, rinsing with tap water, staining in 0.1% crystal violet
solution for 10 min at RT, rinsing in water and air drying. Plaques were quantiﬁed
on a Zeiss AxioObserver microscope equipped with a ×2.5 objective (Department
of Molecular Microbiology Imaging Facility at the Washington University School
of Medicine).
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In vivo efﬁcacy studies. Testing of compounds to prevent reactivation of chronic
infection was based two different protocols were used to test the efﬁcacy of
PheRS inhibitors against chronic infection. In both cases, male and female
C57BL/6 Ifngr1−/− mice were infected by oral gavage with 5 cysts of the ME49Fluc strain isolated from chronically infected CBA/J mice. Compound BRD7929
was formulated at 1 mg/mL in freshly prepared compound resuspension buffer
(vehicle; 10% ETOH, 4% Tween-80 in 1xPBS), aliquoted for single use and
stored at −20 °C. In the ﬁrst protocol, at 48 h post-infection, animals were given
sulfadiazine (0.25 g/L in drinking water) for 20 days post-infection to prevent
death during acute infection and to allow establishment of chronic infection.
Two days after completion of the sulfadiazine treatment, one cohort of mice
were treated once a day with 10 mg/kg BRD7929 by oral gavage for 16 days and
control mice received an equal volume of vehicle during the same time frame.
Animals were monitored for survival and weight loss for 30 days post-treatment.
In a second protocol based on a previously published method27, mice were
treated at 48 h post-infection with sulfadiazine (sulfa; 0.25 g/L in drinking water)
for 20 days or treated with 10 mg/kg BRD7929 by oral gavage once a day for
10 days or 20 days, respectively. All mice were monitored for survival and weight
loss every two days for the duration of treatment and for an additional >20 days
post-treatment. For bioassay, surviving mice were sacriﬁced, brains excised and
homogenized in 1 mL of 1x PBS and 300 μL (~1/3 of donor brain) was administered to naïve C57BL/6 female Ifngr1−/− by oral gavage. Recipient mice were
monitored for 20 days for survival, weight loss, and seroconversion by ELISA.
Testing toxicity against host cells. For the toxicity screen, compounds were tested
in 96-well plates using all the wells as no edge affect was observed. Compounds
were diluted to 40 μM (2x concentration in 10% DMEM, 0.4% DMSO) before
step-wise, 3-fold dilution in 10% DMEM to create 10-dose series (20 μM to 0.001
μM). Host cells were plated in black, μ-Clear 96-well plates (Greiner Bio-One).
We compared several lineages including HepG2 (human hepatocellular carcinoma (ATCC-HB-8065)), THP-1 (human monocytic tumor line), SH-SY5Y
(human neuroblastoma (ATCC CRL-2266)), A549 (human lung carcinoma
(ATCC CRM-CCL-185)) and Caco-2 (human intestinal adenocarcinoma (ATCC
HTB-37)) and HFF (primary human foreskin ﬁbroblast) obtained from the
laboratory of John Boothroyd at Stanford University. Cells were maintained in
culture media according to the formulations recommended by ATCC. Cells were
plated at a density (ranging from of 5 × 103 to 2 × 104 cells/well (100 μL vol))
resulting in sub-conﬂuent monolayers to allow expansion during the 2 day
growth assay. THP-1 cells were treated with 10 ng/ml phorbol 12-myristate 13acetate (PMA) for 24 h to differentiate into macrophages before compound
addition. For all other cells, compounds were added at 6 h post seeding to host
cells containing plates (200 μL ﬁnal volume, 0.2% DMSO) and incubated in
culture medium at 37 °C supplemented with 5% CO2. At 44 h post compound
addition (50 h total growth time), culture media was aspirated and replaced with
Live Imaging solution (ThermoFisher) supplemented with 10 μg/mL Hoeschst
33342 (Sigma) for 20 min at 37 °C. The plates were imaged on an InCell Analyzer
2000 (DAPI, ×10 objective, 4 images/well) and nuclei quantiﬁed using the InCell
Developer Software package (v1.9) All media handling, compound dilution and
imaging steps were directed by a Dual Pod Biomek FX driven by the SAMI EX
software system to ensure accurate and reproducible data across replicates (HighThroughput Screening Center, Washington University School of Medicine).
Alternatively, plates ﬁxed with 4% formaldehyde for 10 min and stained with
10 μg/mL Hoeschst 33342 (Sigma) for 20 min and imaged using a Cytation 3
multi-mode imager (DAPI, 10x objective, 4 images/well) and nuclei quantiﬁed
using the Gen5 imager software (v3.08). Assays were repeated with two technical
replicates within each of two independent biological replicates.
Statistical analysis. All statistical analyses were conducted using Prism 9
(GraphPad Software, Inc.). Dose–response inhibition curves for parasite and host
cell toxicity screens (EC50 values) were generated using (Log(inhibitor) vs. normalized response—Variable slope) function. EC90 and 3xEC90 values were generated using (Log (agonist) vs normalized response—FindECanything) calculator.
For multiple comparisons, two-way ANOVA analysis function using either Sidák’s
multiple comparisons test or Dunnett’s multiple comparisons test was applied as
indicated.
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